Clinical trials
Multiple Myeloma trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
130 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 14 |
| 2019 | 19 |
| 2020 | 10 |
| 2021 | 24 |
| 2022 | 22 |
| 2023 | 15 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 130 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shanghai Changzheng Hospital | 6 |
| Institute of Hematology & Blood Diseases Hospital, China | 5 |
| Peking Union Medical College Hospital | 5 |
| The First Affiliated Hospital of Soochow University | 5 |
| Hebei Senlang Biotechnology Inc., Ltd. | 4 |
| Zhejiang University | 4 |
| Chinese PLA General Hospital | 3 |
| Peking University People's Hospital | 3 |
| Sun Yat-sen University | 3 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 130 |
| Recurrence | 12 |
| Lymphoma | 7 |
| Neoplasm, Residual | 5 |
| Hematologic Neoplasms | 3 |
| Leukemia, Plasma Cell | 3 |
| Burkitt Lymphoma | 2 |
| Esophageal Neoplasms | 2 |
| Leukemia | 2 |
| Lung Neoplasms | 2 |
Trials
Showing 1 to 25 of 130. Each trial links to its page on Pharma Observatory.
30 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.